Schedule of Disaggregation of Revenues |
During the years ended December 31, 2019, 2018 and 2017, the Company recorded product sales, net, as follows:
|
|
Year Ended December 31, |
|
(In thousands) |
|
2019 |
|
|
2018 |
|
|
2017 |
|
VIVITROL |
|
$ |
335,365 |
|
|
$ |
302,609 |
|
|
$ |
269,321 |
|
ARISTADA/ARISTADA INITIO |
|
|
189,134 |
|
|
|
147,725 |
|
|
|
93,513 |
|
Total product sales, net |
|
$ |
524,499 |
|
|
$ |
450,334 |
|
|
$ |
362,834 |
|
|
Schedule of Disaggregation of Revenues |
During the years ended December 31, 2019, 2018 and 2017, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:
|
|
Year Ended December 31, 2019 |
|
(In thousands) |
|
Manufacturing Revenue |
|
|
Royalty Revenue |
|
|
Total |
|
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA |
|
$ |
— |
|
|
$ |
256,947 |
|
|
$ |
256,947 |
|
RISPERDAL CONSTA |
|
|
50,433 |
|
|
|
15,950 |
|
|
|
66,383 |
|
AMPYRA/FAMPYRA |
|
|
22,071 |
|
|
|
15,170 |
|
|
|
37,241 |
|
Other |
|
|
31,750 |
|
|
|
55,561 |
|
|
|
87,311 |
|
|
|
$ |
104,254 |
|
|
$ |
343,628 |
|
|
$ |
447,882 |
|
|
|
Year Ended December 31, 2018 |
|
(In thousands) |
|
Manufacturing Revenue |
|
|
Royalty Revenue |
|
|
Total |
|
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA |
|
$ |
— |
|
|
$ |
241,423 |
|
|
$ |
241,423 |
|
RISPERDAL CONSTA |
|
|
52,770 |
|
|
|
18,352 |
|
|
|
71,122 |
|
AMPYRA/FAMPYRA |
|
|
53,044 |
|
|
|
54,009 |
|
|
|
107,053 |
|
Other |
|
|
27,214 |
|
|
|
79,863 |
|
|
|
107,077 |
|
|
|
$ |
133,028 |
|
|
$ |
393,647 |
|
|
$ |
526,675 |
|
|
|
Year Ended December 31, 2017 |
|
(In thousands) |
|
Manufacturing Revenue |
|
|
Royalty Revenue |
|
|
Total |
|
INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA |
|
$ |
— |
|
|
$ |
214,931 |
|
|
$ |
214,931 |
|
RISPERDAL CONSTA |
|
|
64,793 |
|
|
|
20,129 |
|
|
|
84,922 |
|
AMPYRA/FAMPYRA |
|
|
55,373 |
|
|
|
61,646 |
|
|
|
117,019 |
|
Other |
|
|
32,655 |
|
|
|
55,781 |
|
|
|
88,436 |
|
|
|
$ |
152,821 |
|
|
$ |
352,487 |
|
|
$ |
505,308 |
|
|